175 related articles for article (PubMed ID: 24531303)
61. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
62. Prognostic Significance of Metabolic Parameters by
Lee J; Cho YS; Kim J; Shim YM; Lee KH; Choi JY
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572388
[TBL] [Abstract][Full Text] [Related]
63. The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer.
Kwon SH; Hyun SH; Yoon JK; An YS; Oh YT; Choi JH; Park KJ; Lee SJ
Medicine (Baltimore); 2016 Feb; 95(5):e2772. PubMed ID: 26844524
[TBL] [Abstract][Full Text] [Related]
64. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
65. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
[TBL] [Abstract][Full Text] [Related]
66. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
67. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer.
Chung HH; Kim JW; Han KH; Eo JS; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Gynecol Oncol; 2011 Feb; 120(2):270-4. PubMed ID: 21109300
[TBL] [Abstract][Full Text] [Related]
68. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.
Ulaner GA; Eaton A; Morris PG; Lilienstein J; Jhaveri K; Patil S; Fazio M; Larson S; Hudis CA; Jochelson MS
Cancer Med; 2013 Oct; 2(5):725-33. PubMed ID: 24403238
[TBL] [Abstract][Full Text] [Related]
69. High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.
Chan DL; Bernard EJ; Schembri G; Roach PJ; Johnson M; Pavlakis N; Clarke S; Bailey DL
Neuroendocrinology; 2020; 110(11-12):950-958. PubMed ID: 31711058
[TBL] [Abstract][Full Text] [Related]
70. Prognostic value of preoperative intratumoral FDG uptake heterogeneity in early stage uterine cervical cancer.
Chung HH; Kang SY; Ha S; Kim JW; Park NH; Song YS; Cheon GJ
J Gynecol Oncol; 2016 Mar; 27(2):e15. PubMed ID: 26768781
[TBL] [Abstract][Full Text] [Related]
71. Intra-tumor metabolic heterogeneity of gastric cancer on
Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
[TBL] [Abstract][Full Text] [Related]
72. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
73. Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Evangelista L; Cervino AR; Ghiotto C; Saibene T; Michieletto S; Fernando B; Orvieto E; Guarneri V; Conte P
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1648-1655. PubMed ID: 26025244
[TBL] [Abstract][Full Text] [Related]
74. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
[TBL] [Abstract][Full Text] [Related]
75. Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.
Roh JL; Kim JS; Kang BC; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2014 Dec; 110(7):869-75. PubMed ID: 25088392
[TBL] [Abstract][Full Text] [Related]
76. Use of
Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
[No Abstract] [Full Text] [Related]
77.
Qin C; Shao F; Hu F; Song W; Song Y; Guo J; Lan X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1083-1093. PubMed ID: 31807883
[TBL] [Abstract][Full Text] [Related]
78. Prognostic value of baseline
Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
[TBL] [Abstract][Full Text] [Related]
79. FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.
Taghipour M; Wray R; Sheikhbahaei S; Wright JL; Subramaniam RM
AJR Am J Roentgenol; 2016 Apr; 206(4):846-55. PubMed ID: 27003053
[TBL] [Abstract][Full Text] [Related]
80. Harmonized pretreatment quantitative volume-based
Kitajima K; Miyoshi Y; Sekine T; Takei H; Ito K; Suto A; Kaida H; Daisaki H; Yamakado K
Hell J Nucl Med; 2020; 23(3):272-289. PubMed ID: 33367302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
